Skip to main content
. 2021 May 3;118(19):e2100939118. doi: 10.1073/pnas.2100939118

Fig. 2.

Fig. 2.

IDO is induced by decitabine and is required for sustained disease remission. (A) IDO1 gene expression of BMDCs of C57BL/6 mice treated with IFNγ and/or decitabine was determined by qPCR. Values are the mean ± SEM (N = 3). (B) C57BL/6 mice were immunized with bovine type II collagen in CFA and treated with decitabine (1 mg⋅kg−1⋅d−1) or vehicle for 4 d. Spleens and lymph nodes were harvested on day 11 after immunization. IDO1 gene expression was determined by qPCR. Values are the mean ± SEM (N = 3). (C and D) Wild-type and Ido1−/− mice with CIA were treated for 4 d with decitabine (1 mg⋅kg−1⋅d−1) and monitored for 20 d. (C) Clinical scores. (D) % relapsed mice. (E and F) Wild-type and Ido1−/− mice treated with decitabine from C were culled on day 20. Lymph node cells were stained with lineage-specific transcription factors (E) and MFI of Treg immunoregulatory markers was determined by gating on Treg cells from E (F). *P < 0.05, **P < 0.01, ***P < 0.001.